Table 1. Patients’ characteristics... | American Society of Hematology

Table 1.

Patients’ characteristics

Patient no.	Disease status at enrollment	EM disease at enrollment	Previous SCT	Previous tisagenlecleucel	Previous blinatumomab/inotuzumab	Lines of treatment before CARPALL	Disease level by flow/mol MRD before lymphodepletion	CD19/CD22 expression at enrollment
1	Second relapse	No	No	Yes	Yes/yes	6	0.12% 1.3 × 10⁻³	+/+
2	Second relapse	CNS	Yes	No	Yes/no	5	0.39% 1 × 10⁻²	+/+
3	Third relapse	No	Yes	Yes	No/no	6	ND/6 × 10⁻²	+/+
4	Second relapse	CNS	Yes	No	No/no	3	0.069% 7 × 10⁻⁴	+/+
5	Second relapse	CNS	Yes	No	No/no	3	Negative/negative	+/+
6	Second relapse	No	Yes	Yes	Yes/no	4	85%	+/+
7	Second relapse	Adenopathy/pelvic mass	No	No	Yes/yes	3	12% 2.8 × 10⁻¹	10% Blasts CD19 neg/+
8	First relapse	No	No	No	No/no	2	2.3%/ND	Neg/+
9	Second relapse	No	No	Yes	No/no	4	18.6%	100% Blasts CD19 neg/5% blasts CD22 neg
10	Second relapse	Chest wall	Yes	No	Yes/no	3	Negative/negative	+/+
11	First relapse	CNS and spine	No	No	Yes/no	3	7.4%	+/+
12	First relapse	CNS	No	No	No/no	2	Negative/negative	+/+

Patient no.	Disease status at enrollment	EM disease at enrollment	Previous SCT	Previous tisagenlecleucel	Previous blinatumomab/inotuzumab	Lines of treatment before CARPALL	Disease level by flow/mol MRD before lymphodepletion	CD19/CD22 expression at enrollment
1	Second relapse	No	No	Yes	Yes/yes	6	0.12% 1.3 × 10⁻³	+/+
2	Second relapse	CNS	Yes	No	Yes/no	5	0.39% 1 × 10⁻²	+/+
3	Third relapse	No	Yes	Yes	No/no	6	ND/6 × 10⁻²	+/+
4	Second relapse	CNS	Yes	No	No/no	3	0.069% 7 × 10⁻⁴	+/+
5	Second relapse	CNS	Yes	No	No/no	3	Negative/negative	+/+
6	Second relapse	No	Yes	Yes	Yes/no	4	85%	+/+
7	Second relapse	Adenopathy/pelvic mass	No	No	Yes/yes	3	12% 2.8 × 10⁻¹	10% Blasts CD19 neg/+
8	First relapse	No	No	No	No/no	2	2.3%/ND	Neg/+
9	Second relapse	No	No	Yes	No/no	4	18.6%	100% Blasts CD19 neg/5% blasts CD22 neg
10	Second relapse	Chest wall	Yes	No	Yes/no	3	Negative/negative	+/+
11	First relapse	CNS and spine	No	No	Yes/no	3	7.4%	+/+
12	First relapse	CNS	No	No	No/no	2	Negative/negative	+/+

+, positive; CNS, central nervous system; EM, extramedullary; mol, molecular; ND, not determined; neg, negative.